The Food Safety and Standards Authority of India (FSSAI) notified the FSS (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, and Prebiotic and Probiotic Food) Regulations — “FSS (HSND) 2022” — consolidating and replacing the earlier 2016 nutraceutical framework. Every Central-licensed nutraceutical manufacturer in India now operates under this regime, yet the product-level output of this regulatory apparatus is not aggregated, published, or released in machine-readable form at the national level. We contribute the first public corpus of FSSAI Central-Licensed nutraceutical products with per-product metadata: 71 products filed and licensed under FSSAI Central License 10020064002342 to Nutriley Healthcare Pvt Ltd, Hisar, Haryana, over the window 2023–2025. Each record captures regulatory class (NC for Nutraceutical Category vs HS for Health Supplement), dosage form, approval date, and ingredient list derived from the filed composition statements. We release 68 of the 71 records (three of the most recent approvals held under a six-month commercial-protection policy), under CC BY-NC 4. 0. The dataset captures 77 unique botanical/active Latin names; the top-five are Ginkgo biloba, Curcuma longa, Tribulus terrestris, Camellia sinensis, and Panax ginseng. A separate file documents the filing of all five annual Form-D1 returns (2020-21 through 2024-25) without disclosing per-SKU manufacturing quantities, which are operationally sensitive. Paired with a companion AYUSH Ayurvedic corpus (10. 5281/zenodo. 19680209), this release offers a two-regime view of the Indian natural-ingredient health-product sector and serves as an input to a forthcoming Unified Pharmacopoeia Knowledge Graph.
Aggarwal et al. (Tue,) studied this question.